person · Reporting owner

Fischer Seth H. Z.

Disclosed activity across 7 companies

Tapewire entity: 30803
SEC CIK: 0001573553

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Milestone Pharmaceuticals Inc.MIST · Entity 6561	Director	June 10, 2026	June 12, 2026
Streamex Corp.BSGM · Entity 1816	Director	October 16, 2018	November 10, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Milestone Pharmaceuticals Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10	Direct	77,000	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.

Streamex Corp.

Report date October 16, 2018 · Filed November 10, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	60,000	Reported balance After 2018-10-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-10-16 · Grant · Acquired 50,000 · Balance 60,000 F1: On September 10, 2018, BioSig Technologies, Inc. effected a 1-for-2.5 reverse stock split (the "Stock Split"). The number of shares reported have been adjusted for the Stock Split.

Filing footnotes · ownership attribution and instrument terms

F1: On September 10, 2018, BioSig Technologies, Inc. effected a 1-for-2.5 reverse stock split (the "Stock Split"). The number of shares reported have been adjusted for the Stock Split.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AGILE THERAPEUTICS INC

Report date August 26, 2024 · Filed August 26, 2024

Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-08-26 transaction · row 1 1 source row Row 1 · 2024-08-26 · Disposition to issuer · Disposed 976 · Balance 0 F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 976 shares of Common Stock were converted into the right to receive into the right to receive a cash payment of $1.52 (the "Merger Consideration") per share of Common Stock, for an aggregate of $1,484, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person

Filing footnotes · ownership attribution and instrument terms

F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 976 shares of Common Stock were converted into the right to receive into the right to receive a cash payment of $1.52 (the "Merger Consideration") per share of Common Stock, for an aggregate of $1,484, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person

Esperion Therapeutics, Inc.

Report date July 13, 2026 · Filed July 13, 2026

Section 16 reporting ended · disclosed 2026-07-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-07-13 transaction · row 1 1 source row Row 1 · 2026-07-13 · Disposition to issuer · Disposed 141,023 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2033-06-15	Direct	Reported balance After 2026-07-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-13 · Disposition to issuer · Disposed 21,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2034-05-23	Direct	Reported balance After 2026-07-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-07-13 · Disposition to issuer · Disposed 32,500 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-05-29	Direct	Reported balance After 2026-07-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-07-13 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.

F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.

MARINUS PHARMACEUTICALS, INC.

Report date February 07, 2025 · Filed February 11, 2025

Section 16 reporting ended · disclosed 2025-02-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,300	Reported balance After 2025-02-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-02-07 · Disposition to issuer · Disposed 12,707 · Balance 2,300 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2: The reported amount reflects an adjustment to correct a clerical error that previously underreported the Reporting Person's holdings by 2,081 shares of Common Stock. No reportable transactions were omitted from previous filings in connection with the clerical error underlying this correction.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-02-11 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2025-02-11 · Disposition to issuer · Disposed 2,300 · Balance 0 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F3: Represents 2,300 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2034-06-18	Direct	0	Reported balance After 2025-02-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-02-11 · Disposition to issuer · Disposed 10,450 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2034-01-18	Direct	0	Reported balance After 2025-02-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-02-11 · Disposition to issuer · Disposed 20,900 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2033-01-26	Direct	0	Reported balance After 2025-02-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-02-11 · Disposition to issuer · Disposed 16,200 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2032-02-04	Direct	0	Reported balance After 2025-02-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-02-11 · Disposition to issuer · Disposed 12,375 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.60 · Expires 2031-01-15	Direct	0	Reported balance After 2025-02-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-02-11 · Disposition to issuer · Disposed 16,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2030-01-08	Direct	0	Reported balance After 2025-02-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-02-11 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.84 · Expires 2029-02-26	Direct	0	Reported balance After 2025-02-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-02-11 · Disposition to issuer · Disposed 8,750 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.76 · Expires 2027-12-06	Direct	0	Reported balance After 2025-02-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-02-11 · Disposition to issuer · Disposed 8,750 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2027-01-17	Direct	0	Reported balance After 2025-02-11 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-02-11 · Disposition to issuer · Disposed 2,625 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.92 · Expires 2026-09-06	Direct	0	Reported balance After 2025-02-11 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-02-11 · Disposition to issuer · Disposed 3,850 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.

F2: The reported amount reflects an adjustment to correct a clerical error that previously underreported the Reporting Person's holdings by 2,081 shares of Common Stock. No reportable transactions were omitted from previous filings in connection with the clerical error underlying this correction.

F3: Represents 2,300 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.

SPECTRUM PHARMACEUTICALS INC

Report date July 31, 2023 · Filed August 01, 2023

Section 16 reporting ended · disclosed 2023-08-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2023-07-31 transaction · row 1 1 source row Row 1 · 2023-07-31 · Disposition to issuer · Disposed 54,066 · Balance 0 F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13	Direct	0	Reported balance After 2023-07-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-07-31 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger.

F2: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,

F3: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration.

VIVUS INC

Report date January 01, 2018 · Filed January 03, 2018

Section 16 reporting ended · disclosed 2018-01-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	633,978	Reported balance After 2018-01-01 transaction · row 1 1 source row Row 1 · 2018-01-01 · Disposition to issuer · Disposed 2,102 · Balance 633,978 F1: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2021 Filed Jun 22, 2021 17:18 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantCommon Stock, $0.001 par value	14,277	$0.00	$0.00	Disclosure SEC source: 0001209191-21-042453 · doc4.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,777 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 17, 2022 or (2) the date of the company's 2022 Annual Meeting of Stockholders. Read SEC document
June 08, 2021 Filed Jun 10, 2021 19:13 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	GrantEmployee Stock Option (Right to Buy) · Derivative	29,905	$0.00 Strike: $1.53	$0.00	Disclosure SEC source: 0001104659-21-079621 · tm2119345-4_4seq1.xml · derivative · entry 2 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,905 Underlying: Common Stock · 29,905 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option was granted on June 8, 2021 and vests in full on June 8, 2022, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document
June 08, 2021 Filed Jun 10, 2021 19:13 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	GrantCommon Stock	24,510	$0.00	$0.00	Disclosure SEC source: 0001104659-21-079621 · tm2119345-4_4seq1.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,852 F1 · shares: These shares represent restricted stock units that were granted on June 8, 2021, which will vest and be settled in common stock on June 8, 2022, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document
January 15, 2021 Filed Jan 19, 2021 20:12 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock option (right to buy) · Derivative	16,500	$0.00 Strike: $12.60	$0.00	Disclosure SEC source: 0001104659-21-005518 · tm213599-4_4seq1.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-01-15 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 12 equal monthly installments, commencing on 1/31/21. Read SEC document
June 18, 2020 Filed Jun 19, 2020 17:49 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001209191-20-038021 · doc4.xml · derivative · entry 2 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-06-18 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of June 18, 2021, 2022 and 2023, respectively. Read SEC document
June 18, 2020 Filed Jun 19, 2020 17:49 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantCommon Stock, $0.001 par value	30,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-038021 · doc4.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 18, 2021 or (2) the date of the company's 2021 Annual Meeting of Stockholders. Read SEC document
June 09, 2020 Filed Jun 11, 2020 17:22 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	GrantEmployee Stock Option (Right to Buy) · Derivative	22,606	$0.00 Strike: $2.80	$0.00	Disclosure SEC source: 0001104659-20-072489 · a4.xml · derivative · entry 2 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,606 Underlying: Common Stock · 22,606 shares Expires 2030-06-08 F2 · derivative.exercise_date: The option was granted on June 9, 2020 and vests in full on June 9, 2021, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document
June 09, 2020 Filed Jun 11, 2020 17:22 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	GrantCommon Stock	13,393	$0.00	$0.00	Disclosure SEC source: 0001104659-20-072489 · a4.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,342 F1 · shares: These shares represent restricted stock units that were granted on June 9, 2020, which will vest and be settled in common stock on June 9, 2021, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document
April 23, 2020 Filed Apr 27, 2020 18:33 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $2.79	$0.00	Disclosure SEC source: 0001209191-20-025873 · doc4.xml · derivative · entry 2 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-04-23 F2 · derivative.exercise_date: 25% of the option shares vested on April 23, 2020. The remaining option shares shall vest in equal amounts of 25% of the total shares underlying the option shares on each anniversary of the grant date over the next three years. Read SEC document
April 23, 2020 Filed Apr 27, 2020 18:33 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantCommon Stock, $0.001 par value	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-20-025873 · doc4.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · shares: 100% of the restricted shares shall vest on June 18, 2020. Read SEC document
January 08, 2020 Filed Jan 10, 2020 16:52 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock option (right to buy) · Derivative	100,000	$0.00 Strike: $2.07	$0.00	Disclosure SEC source: 0001104659-20-003098 · a4.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-08 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 12 equal monthly installments, commencing on 1/31/20. Read SEC document
June 06, 2019 Filed Jun 7, 2019 16:31 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	GrantEmployee Stock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001104659-19-034553 · a4.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option was granted on June 6, 2019 and vests in full on June 6, 2020, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document
February 26, 2019 Filed Feb 28, 2019 18:59 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock option (right to buy) · Derivative	35,000	$0.00 Strike: $3.96	$0.00	Disclosure SEC source: 0001104659-19-011638 · a4.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: 5,833 options to purchase shares of common stock vest immediately on 2/26/19. The remainder vest in 10 equal monthly installments commencing 3/1/19. Read SEC document
October 16, 2018 Filed Nov 10, 2018 01:15 UTC	Streamex Corp. BSGM · Entity 1816	GrantCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001185185-18-001972 · ownership.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · balance_after: On September 10, 2018, BioSig Technologies, Inc. effected a 1-for-2.5 reverse stock split (the "Stock Split"). The number of shares reported have been adjusted for the Stock Split. Read SEC document
June 08, 2018 Filed Jun 8, 2018 17:03 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	Exercise / conversionRestricted Stock Units · Derivative	17,949	$0.00	$0.00	Disclosure SEC source: 0001104659-18-039222 · a4.xml · derivative · entry 3 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,949 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 8, 2017, the Reporting Person was granted 17,949 restricted stock units, vesting in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attended at least 75% of the board meetings held during the year of board service. F3 · derivative.expiration_date: On June 8, 2017, the Reporting Person was granted 17,949 restricted stock units, vesting in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attended at least 75% of the board meetings held during the year of board service. Read SEC document
June 08, 2018 Filed Jun 8, 2018 17:03 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	Exercise / conversionCommon Stock	17,949	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-039222 · a4.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 07, 2018 Filed Jun 8, 2018 17:03 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	GrantEmployee Stock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $0.60	$0.00	Disclosure SEC source: 0001104659-18-039222 · a4.xml · derivative · entry 2 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-06 F2 · derivative.exercise_date: The option was granted on June 7, 2018 and vests in full on June 7, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document
January 01, 2018 Filed Jan 3, 2018 19:11 UTC	VIVUS INC VVUS · Entity 151460	Disposition to issuerCommon Stock	2,102	$0.50	$1,051.00	Disclosure SEC source: 0001123292-18-000035 · edgar.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Consultant 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633,978 F1 · kind: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability. Read SEC document
December 06, 2017 Filed Dec 8, 2017 16:05 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock option (right to buy) · Derivative	35,000	$0.00 Strike: $6.19	$0.00	Disclosure SEC source: 0001104659-17-072519 · a4.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-12-06 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 12 equal monthly installments commencing 1/1/18. Read SEC document
June 08, 2017 Filed Jun 9, 2017 17:03 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	GrantRestricted Stock Units · Derivative	17,949	$0.00	$0.00	Disclosure SEC source: 0001104659-17-038462 · a4.xml · derivative · entry 2 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 Underlying: Common Stock · 17,949 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 8, 2017 and vest in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F3 · derivative.expiration_date: The restricted stock units were granted on June 8, 2017 and vest in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document
June 08, 2017 Filed Jun 9, 2017 17:03 UTC	AGILE THERAPEUTICS INC AGRX · Entity 87994	GrantEmployee Stock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $3.90	$0.00	Disclosure SEC source: 0001104659-17-038462 · a4.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option was granted on June 8, 2017 and vests in full on June 8, 2018, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document
January 27, 2017 Filed Jan 31, 2017 18:45 UTC	VIVUS INC VVUS · Entity 151460	GrantEmployee Stock Option (right to buy) · Derivative	1,000,000	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001123292-17-000302 · edgar.xml · derivative · entry 2 Fischer Seth H. Z. · CIK 0001573553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2024-01-27 F3 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares underlying the option will vest and become exercisable on January 27, 2018, and one forty-eighth (1/48th) of the total number of shares underlying the option will vest on the 27th of each month thereafter, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document
January 27, 2017 Filed Jan 31, 2017 18:45 UTC	VIVUS INC VVUS · Entity 151460	GrantCommon Stock	150,000	$0.00	$0.00	Disclosure SEC source: 0001123292-17-000302 · edgar.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,080 F1 · security: Each restricted stock unit represents a contingent right to receive one share of VIVUS, Inc. common stock. F2 · shares: The restricted stock units vest according to the following schedule: twenty-five percent (25%) of the total restricted stock units vest on January 27, 2018 with an additional six and one quarter percent (6.25%) of the total restricted stock units vesting quarterly thereafter (i.e., April 27th, July 27th, October 27th, and January 27th) until all of the restricted stock units are vested, subject to such individual continuing to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document
January 17, 2017 Filed Jan 19, 2017 17:19 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantRestricted stock · Derivative	4,500	$0.00	$0.00	Disclosure SEC source: 0001104659-17-003116 · a4.xml · derivative · entry 2 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each share of restricted stock represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: All shares of restricted stock vest on 1/17/18. F4 · derivative.expiration_date: Not applicable. Read SEC document
January 17, 2017 Filed Jan 19, 2017 17:19 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock option (right to buy) · Derivative	10,500	$0.00 Strike: $1.21	$0.00	Disclosure SEC source: 0001104659-17-003116 · a4.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2027-01-17 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 12 equal monthly installments commencing 1/31/17. Read SEC document
September 26, 2016 Filed Sep 28, 2016 18:25 UTC	VIVUS INC VVUS · Entity 151460	GrantCommon Stock	300,000	$0.00	$0.00	Disclosure SEC source: 0001123292-16-002784 · edgar.xml · nonDerivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,080 F1 · security: Each restricted stock unit represents a contingent right to receive one share of VIVUS, Inc. common stock. F2 · shares: The restricted stock units vest according to the following schedule: 50% of the total restricted stock units vest on January 22, 2017 with an additional 12.5% of the total restricted stock units vesting on each of April 22, 2017, July 22, 2017, October 22, 2017 and January 22, 2018, subject to such individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document
January 22, 2016 Filed Sep 28, 2016 18:25 UTC Amendment	VIVUS INC VVUS · Entity 151460	GrantEmployee Stock Option (right to buy) · Derivative	1,000,000	$0.00 Strike: $1.06	$0.00	Disclosure SEC source: 0001123292-16-002785 · edgar.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2023-01-22 F1 · kind: The original Form 4 for the transaction, filed on January 26, 2016, is being amended in connection with the terms of a Stock Option Acknowledgement entered into between VIVUS, Inc. and Mr. Fischer on September 26, 2016, whereby the portion of the original January 22, 2016 stock option grant, that was erroneously issued in excess of the limitations under the VIVUS, Inc. 2010 Equity Inventive Plan, was cancelled. F1 · shares: The original Form 4 for the transaction, filed on January 26, 2016, is being amended in connection with the terms of a Stock Option Acknowledgement entered into between VIVUS, Inc. and Mr. Fischer on September 26, 2016, whereby the portion of the original January 22, 2016 stock option grant, that was erroneously issued in excess of the limitations under the VIVUS, Inc. 2010 Equity Inventive Plan, was cancelled. F2 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares underlying the option shall vest and become exercisable on January 22, 2017, and one forty-eighth (1/48th) of the total number of shares underlying the option will vest and become exercisable on the 22nd of each month thereafter, subject to such individual continuing to be a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.